Investor Area

Home / Investor Area / News / SCENESSE® receives US FDA orphan designation for cutaneous porphyrias
 

SCENESSE® receives US FDA orphan designation for cutaneous porphyrias

 

10 February 2016

 

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its lead drug SCENESSE® (afamelanotide 16mg) has received an additional orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for the treatment of cutaneous variants of porphyria. The ODD recognises the potential of afamelanotide to treat or prevent symptoms in rare forms of porphyria and offers incentives to Clinuvel to develop the drug for these patients.

 

Download PDF for more